Has Olakunle Akinboboye, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,859,406 in general payments to Olakunle Akinboboye, MD across 1,432 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Olakunle Akinboboye, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Olakunle Akinboboye, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Olakunle Akinboboye, MD

Internal Medicine · Laurelton, NYNPI 1780632844

Payments from drug & device makers

$1,859,406in general payments, 2019–2025

Across 1,432 payments — averaging $1298.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$407K
Alnylam Pharmaceuticals Inc.$249K
Janssen Research & Development, LLC$181K
Pfizer$149K
Vivaquant Inc, Dba Rhythm Express$132K
Akcea Therapeutics, Inc.$110K
plus $631K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	133	$407,418
Alnylam Pharmaceuticals Inc.	230	$249,271
Janssen Research & Development, LLC	32	$180,966
Pfizer	109	$148,518
Vivaquant Inc, Dba Rhythm Express	3	$131,896
Akcea Therapeutics, Inc.	62	$110,333
Novartis	83	$102,551
Boehringer Ingelheim Pharma GmbH & Co.kg	25	$91,492
Astrazeneca UK Limited	2	$87,230
Bayer	77	$82,512
Boehringer Ingelheim International GmbH	129	$66,738
Exact Sciences	9	$61,257
Amgen	31	$59,146
Bridgebio Pharma, Inc.	10	$14,023
Eidos Therapeutics, Inc.	4	$13,865
Jazz Pharmaceuticals Inc.	12	$12,955
E.r. Squibb & Sons, L.L.C.	27	$9,986
Ionis Pharmaceuticals, Inc.	4	$6,502
Sanofi US Services Inc.	1	$4,650
Merck	68	$4,129
Sobi, Inc	12	$2,814
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	4	$2,644
Novo Nordisk	73	$1,718
Johnson & Johnson	60	$1,396
Boehringer Ingelheim	45	$1,171
Sanofi-aventis U.S. LLC	40	$756
Lilly USA, LLC	35	$738
Abbott	13	$326
Dexcom, Inc.	12	$288
Amarin Pharma, Inc.	10	$244
Medtronic	2	$196
Edwards Lifesciences	6	$181
Actelion Pharmaceuticals US, Inc.	6	$170
Lexicon Pharmaceuticals, Inc.	6	$163
Kowa Pharmaceuticals America, Inc.	8	$139
Esperion Therapeutics, Inc.	4	$95
Mannkind Corporation	4	$83
Global Blood Therapeutics, Inc.	4	$79
Arbor Pharmaceuticals, Inc.	4	$69
Boston Scientific	3	$67
Scpharmaceuticals Inc.	3	$63
Cvrx, Inc.	2	$60
Vivus LLC	3	$57
Baxter Healthcare	2	$50
Kestra Medical Technology Services, Inc.	2	$47
AbbVie	2	$37
Currax Pharmaceuticals LLC	2	$33
Acarix USA Inc.	1	$31
Regeneron Healthcare Solutions, Inc.	2	$31
Bardy Diagnostics, Inc.	1	$25
Biogen	1	$25
Biocompatibles, Inc.	1	$24
GSK	1	$24
Astellas Pharma US Inc	1	$22
Medicomp Inc	1	$22
Genentech USA, Inc.	1	$18
Lundbeck LLC	1	$17
Azurity Pharmaceuticals, Inc.	1	$17
Renalytix AI, Inc.	1	$16
Itamar Medical Inc	1	$15

How this compares

$1,859,406 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York →

Medicare billing

Part B allowed, 2024

$565,059

Medicare patients

331

Services billed

5,592

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Laurelton

Helena YuNew York$50.9M
Neha KordeNew York$21.2M
Karen AutioNew York$18.5M
Ingo MellinghoffNew York$16.1M
Gopakumar IyerNew York$12.4M
David DoveEast Hampton$12.3M
Robert CupeloEast Syracuse$10.6M
Patrick ReaganRochester$9.4M
Sally LauNew York$8.4M
Angela BrancheRochester$7.9M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →